Device Trial Radar · NCT07909421
A Study to Evaluate the Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
326
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jan 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Galderma R&DNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0112 for cheek augmentation and correction of midface contour deficiencies. Approximately 326 subjects will be randomized (1:1) to either treatment with GP0112 or Juvéderm Voluma XC(also known as Juvéderm Voluma with lidocaine).
Conditions
- Cheek Wrinkles
- Midface Contour Deficiencies
Interventions
GP0112Device
Injectable gel
Juvéderm Voluma XCDevice
Injectable gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder rate based on the Blinded Evaluators' live assessment using the Medicis Midface Volume Scale (MMVS).Time frame: At Month 6 after last treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Galderma Investigational Site #6347
Chengdu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.